当前位置: 首页 >> 检索结果
共有 174 条符合本次的查询结果, 用时 5.850264 秒

1. Glucagon-like peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: a Systematic Review and Meta-analysis.

作者: Cho-Hung Chiang.;Aunchalee Jaroenlapnopparat.;Sena Cakir Colak.;Chun-Chiao Yu.;Nutchapon Xanthavanij.;Tsu-Hsien Wang.;Xin Ya See.;Shao-Wei Lo.;Albert Ko.;Yu-Cheng Chang.;Junmin Song.;Yuan Ping Hsia.;Cho-Han Chiang.
来源: Gastroenterology. 2025年
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for glycemic control or weight management in patients with type 2 diabetes mellitus (T2DM) or overweight/obesity. However, there are concerns regarding their association with serious gastrointestinal adverse events though findings have been inconsistent.

2. Prognostic value of platelet-to-lymphocyte ratio in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.

作者: Qingtian Zhou.;Zewen Jiang.;Tingting Ye.;Li Yu.;Qinglian Wang.;Pin Lin.;Yanfeng Shao.
来源: BMC Gastroenterol. 2025年25卷1期437页
The prognostic significance of the Platelet-to-Lymphocyte Ratio (PLR) in patients with hepatocellular carcinoma (HCC) undergoing treatment with immune checkpoint inhibitors (ICIs) remains uncertain. A systematic review and meta-analysis was conducted to assess the prognostic value of PLR in HCC patients receiving ICIs.

3. Comprehensive evaluation of clinical phenotypes and pathogenic features in late-onset monogenic inflammatory bowel disease: a comparative study with infantile-onset cases.

作者: Haoying Liu.;Yinxian Shen.;Jiaxin Xu.;Shangzhan Huang.;TingTing Qin.;Qi Zhou.;Jiazhi Liao.;Fang Xiao.
来源: BMC Gastroenterol. 2025年25卷1期432页
Monogenic inflammatory bowel disease (mIBD) in patients with onset after the age of 16 has been increasingly recognized, but these reports are sporadic and lack a systematic overview, leaving the clinical and genetic characteristics poorly understood. This study aimed to characterize these late-onset mIBD (LO-mIBD), using an infantile-onset population as a control.

4. Neoadjuvant chemotherapy with or without PD-1/PD-L1 inhibitors in resectable esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials.

作者: Ye Zhang.;Jie Chen.;Fenglian Yu.;Wenxiong Zhang.;Yingmei Zhong.
来源: BMC Gastroenterol. 2025年25卷1期416页
Neoadjuvant chemotherapy (NC) is a cornerstone in the management of resectable esophageal squamous cell carcinoma (ESCC). The integration of PD-1/PD-L1 inhibitors into NC (NIC) regimens has shown promise; however, its efficacy and safety remain uncertain. This meta-analysis aims to compare the potential risks and clinical benefits of NIC versus NC in patients with resectable ESCC based on randomized controlled trials (RCTs).

5. Association between the immune-inflammation index and the severity and clinical outcomes of patients with inflammatory bowel disease: a systematic review and meta-analysis.

作者: Peiji Li.;Yilin Wu.;Wei Xiong.;Jiahui Cao.;Mengyun Chen.;Zhaowei Yuan.;Wenxin Guo.;Bing Yang.
来源: BMC Gastroenterol. 2025年25卷1期414页
Existing studies have explored the association between immune-inflammatory indices and inflammatory bowel disease (IBD), but there is a lack of comprehensive evidence. This meta-analysis and systematic review seeks to synthesize the data of available clinical research and offer the latest and comprehensive evidence-based conclusions regarding whether these immune-inflammatory indices can effectively predict the severity, activity, and prognosis of IBD.

6. Effect of synbiotics on the cardiovascular risk factors in patients with non-alcoholic fatty liver: a GRADE assessed systematic review and meta-analysis.

作者: Minfang Lv.;Ghavam Shafagh.;Saiting Yu.
来源: BMC Gastroenterol. 2025年25卷1期407页
Several studies revealed that synbiotics have been beneficial in managing non-alcoholic fatty liver disease (NAFLD), but the findings are conflicting. We aimed to assess the effect of synbiotic supplementation on cardiovascular risk factors in patients with NAFLD.

7. The efficacy of retrograde and antegrade enemas in the management of low anterior resection syndrome in patients undergoing rectal resection: a systematic review and meta-analysis.

作者: Yuan Yuan.;Qi Gao.;Hui Yang.
来源: BMC Gastroenterol. 2025年25卷1期401页
Rectal resection could potentially cause low anterior resection syndrome (LARS). Although recent studies have reported the efficacy of enema against LARS, no systematic review and meta-analysis has been conducted.

8. Association between celiac disease and risk of kidney diseases: a systematic review and meta-analysis.

作者: Sawai S Rathore.;Shifa P Shaikh.;Hyder R Zaidi.;George O Salako.;Chiranjeevee R Saravanan.;Rabiat R Kuranga.;Narendra Yagateela.;Sai T Bandala.;Bijay M Jeswani.
来源: Minerva Gastroenterol (Torino). 2025年
Celiac disease (CD), an autoimmune disorder, has been linked to chronic kidney disease but results are inconsistent. This meta-analysis investigates the association between CD and the risk of kidney disease.

9. The current status and prospects of gut microbiota combined with PD-1/PD-L1 inhibitors in the treatment of colorectal cancer: a review.

作者: Min Deng.;Xiaoyu Li.;Huiming Wu.;Dingwen Xue.;Yize Wang.;Renkai Guo.;Yipeng Cui.;Chenfei Jin.;Fei Luo.;Huiyu Li.
来源: BMC Gastroenterol. 2025年25卷1期380页
Colorectal cancer (CRC) is a common malignant tumor. Immune checkpoint inhibitors (ICIs), particularly those targeting programmed cell death protein 1(PD-1) and programmed cell death ligand 1(PD-L1), have shown promising potential in the treatment of CRC. Specific gut microbiota can modulate the efficacy of ICIs through immune or metabolic pathways. This review summarizes recent advances in the combined application of gut microbiota and PD-1/PD-L1 inhibitors in the treatment of CRC, aiming to provide insights for expanding clinical treatment options for CRC.

10. A systematic review of the epidemiology and risk factors for severity and recurrence of hypertriglyceridemia-induced acute pancreatitis.

作者: Jiongdi Lu.;Zhe Wang.;Wentong Mei.;Kaixin Peng.;Liang Zhang.;Gang Wang.;Kedong Xu.;Zheng Wang.;Yunpeng Peng.;Zipeng Lu.;Xiaolei Shi.;Guotao Lu.;Li Wen.;Feng Cao.; .
来源: BMC Gastroenterol. 2025年25卷1期374页
This systematic review aims to comprehensively assess the epidemiology and identify risk factors associated with the severity and recurrence of hypertriglyceridemia-induced acute pancreatitis (HTG-AP). A search of PubMed, Web of Science, and Cochrane databases was conducted to identify all relevant randomized controlled trials (RCTs), prospective, or retrospective cohort studies on HTG-AP. Data related to epidemiology and risk factors for severity and recurrence of HTG-AP were extracted and analyzed. Seventy-seven studies met the inclusion criteria, comprising 1 RCT, 21 prospective studies, and 55 retrospective studies. A total of 56,617 acute pancreatitis (AP) patients were included, of which 19.99% were diagnosed with HTG-AP (n = 11,315). Compared to non-HTG-AP patients, HTG-AP patients were more likely to be male (68.7% vs. 57.3%) and younger (mean age 41.47 ± 4.32 vs. 50.25 ± 7.70 years). HTG-AP patients exhibited higher mortality rates (up to 20% vs. 15.2%), increased severity (8.3% to 100% vs. 3.8% to 47.2%), and higher recurrence rates (up to 64.8% vs. 23.3%). Analysis of temporal trends from 2002 to 2023 showed a range of HTG-AP prevalence in overall AP patients from 1.6% to 47.6%, with a slight upward trend that was not statistically significant (P = 0.1081). Regional analysis indicated relatively stable prevalence in North America (P = 0.5787), Europe (P = 0.0881), other regions (P = 0.738), while prevalence in China showed a significant increase (P = 0.0119). Thirteen studies investigated risk factors affecting HTG-AP severity, with elevated serum triglyceride (TG) levels associated with increased risk of complications such as pancreatic necrosis, systemic inflammatory response syndrome (SIRS), shock, and multi-organ failure. Additional factors including high neutrophil-to-lymphocyte ratio (NLR), elevated levels of amylase and C-reactive protein (CRP), hypocalcemia, and hypoalbuminemia were also implicated in HTG-AP severity. Smoking history, poor lipid control (TG > 3.1 mmol/L), or recurrent hypertriglyceridemia during follow-up were identified as potential predictors of HTG-AP recurrence. Our findings indicate a stable global prevalence of HTG-AP within AP patients, but a notable increase in China, possibly attributed to socio-economic and dietary factors.

11. Impact of medical therapy on liver transplant eligibility in patients with portopulmonary hypertension: a systematic review.

作者: Matthew T Siuba.;Ahmed Abushamma.;Aman Qureshi.;Shelley Ivary.;Adriano R Tonelli.
来源: Minerva Gastroenterol (Torino). 2025年
Portopulmonary hypertension (PoPH) occurs in roughly 5% of patients evaluated for liver transplant and increases perioperative morbidity and mortality. PoPH patients often succumb to complications of the underlying liver disease, therefore liver transplantation can be a lifesaving intervention. Medical treatment of PoPH optimizes patients for transplantation, but the knowledge on the effect of PH specific therapy on transplant eligibility is limited.

12. Comparison of outcomes between surgery and non-surgery after conversion therapy for advanced gastric cancer with unresectable factors: a systematic review and meta-analysis.

作者: Jiaheng Wu.;Xuetian Du.;Yiqiang He.;Shulin Xian.
来源: BMC Gastroenterol. 2025年25卷1期371页
Advanced gastric cancer (AGC) with unresectable factors presents a significant treatment challenge. Conventional treatments such as systemic chemotherapy, radiotherapy, and immunotherapy can delay disease progression but often yield limited outcomes. For stage III-IV gastric cancer with unresectable factors, conversion therapy based on chemotherapy can achieve tumor downstaging, providing a subset of patients with the opportunity for curative surgery. However, the efficacy of multimodal approaches combining chemotherapy, with or without immunotherapy, and conversion surgery compared to chemotherapy alone remains controversial.

13. A network meta-analysis of different interventional treatment strategies for unresectable hepatocellular carcinoma.

作者: Xing-Yan Le.;Jun-Bang Feng.;Xiao-Li Yu.;Sui-Li Li.;Xiaocai Zhang.;Jiaqing Li.;Chuan-Ming Li.
来源: BMC Gastroenterol. 2025年25卷1期360页
The optimal clinical management of unresectable hepatocellular carcinoma (uHCC) is challenging for clinicians. Bayesian network meta-analysis was conducted to compare the efficacy and safety of different interventional strategies for uHCC.

14. The prognostic value of AST-lymphocyte ratio index in liver cancer patients treated with TACE: a systematic review and single-center retrospective study.

作者: Yali Tian.;Lina Ma.;Shuaiwei Liu.;Xiaoyang Bai.;Nawaz Shah.;Le Zhang.;Xia Wang.;Yuxi Zhang.;Xiangchun Ding.
来源: BMC Gastroenterol. 2025年25卷1期348页
AST-lymphocyte ratio index (ALRI) has been proposed as a potentially prognostic indicator of liver cancer patients underwent transcatheter arterial chemoembolization (TACE) in studies, but the numbers were small and the results were controversial. In this study, we systematically assessed the prognostic value of ALRI in liver cancer patients treated with TACE by integrating meta-analysis with single-center clinical analysis.

15. Association between adhering to a dietary approach to stop hypertension and risk of colorectal cancer: a systematic review and meta-analysis.

作者: Mohammad Mehdi Abbasi.;Paria Babaahmadi.;Fateme Nozari.;Farbod Khosravi.;Zahra Golkar.;Zahra Tavasoli.;Venus Alizadeh.;Marieh Nouriani.;Mohammadsadegh Jafari.;Niloufar Shabani.;Hadis Hashemi Nezhad.;Hossein Soltaninejad.;Mohammad Rahmanian.
来源: BMC Gastroenterol. 2025年25卷1期335页
Colorectal cancer (CRC) is a high incidence cancer and health problem influenced by many factors emphasizes on the importance of identifying risk factors which can be modified. A dietary approach to stop hypertension (DASH) style promotes a balanced nutrition approach that might have effects on CRC. The aim of this study was to analyze existing evidence on the DASH diet's association with CRC.

16. Comments on "Adverse Events Associated With Endoscopic Retrograde Cholangiopancreatography: Systematic Review and Meta-Analysis".

作者: Yizi He.;Haifeng He.;Yongzhi Xie.
来源: Gastroenterology. 2025年

17. Correction: The prevalence of Barrett 's esophagus in Iranian patients with gastrointestinal symptoms: a systematic review and meta-analysis.

作者: Maryam Rashidian.;Fatemeh Bastan.;Hedieh Soltani.;Reza Ghosheni.;Kiyarash Bakhshande.;Mahdi Mohammaditabar.;Yasin Tabatabaei Mehr.;Khaled Rahmani.;Mahmood Bakhtiyari.;Mostafa Qorbani.;Mojgan Forootan.;Mahsa Mohammadi.;Mohsen Rajabnia.
来源: BMC Gastroenterol. 2025年25卷1期330页

18. Triglyceride glucose waist circumference and non alcoholic fatty liver disease: a systematic review and meta analysis.

作者: Ziyi Xin.;Lanlan Feng.;Qingwen Yu.;Yongmin Shi.;Ting Tang.;Xuhan Tong.;Siqi Hu.;Yao You.;Shenghui Zhang.;Xingwei Zhang.;Mingwei Wang.;Jiake Tang.
来源: BMC Gastroenterol. 2025年25卷1期328页
Insulin resistance (IR) plays a noticeable role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). The triglyceride glucose-waist circumference (TyG-WC) index, a novel measure for assessing IR, may hold significant predictive value for NAFLD. However, the relationship between TyG-WC and the risk of NAFLD remains elusive. To investigate this association, this comprehensive meta-analysis was conducted.

19. Evaluation of the efficacy of probiotics in the chemoradiotherapy of colorectal cancer: a meta-analysis of Randomized Controlled Trials.

作者: Rong Yang.;Wei Liu.;Shuiyan Cai.;Xiurong Feng.;Yongjing Chen.;Xiangyu Cheng.;Junjie Ma.;Weiyu Ma.;Zhihui Tian.;Wenhui Yang.
来源: BMC Gastroenterol. 2025年25卷1期312页
We undertook this study to assess the efficacy of probiotics in managing adverse reactions during chemoradiotherapy in patients with colorectal cancer.

20. Artificial intelligence networks for assessing the prognosis of gastrointestinal cancer to immunotherapy based on genetic mutation features: a systematic review and meta-analysis.

作者: Narges Norouzkhani.;Hesam Mobaraki.;Shirin Varmazyar.;Hadis Zaboli.;Zhina Mohamadi.;Golnaz Nikeghbali.;Kamyar Bagheri.;Newsha Marivany.;Mirmehdi Najafi.;Mahdiyeh Nozad Varjovi.;Mohamed Abouzeid.;Hanieh Zeidi Baghrabad.;Pooya Eini.;Aida Azhdarimoghaddam.;Farbod Khosravi.;Mahsa Asadi Anar.
来源: BMC Gastroenterol. 2025年25卷1期310页
Artificial intelligence (AI) networks offer significant potential for predicting immunotherapy outcomes in gastrointestinal cancers by analyzing genetic mutation profiles. Their application in prognosis remains underexplored. This systematic review and meta-analysis aim to evaluate the effectiveness of AI-based models, which refers to systems utilizing artificial intelligence to analyze data and make predictions, in predicting immunotherapy responses in gastrointestinal cancers using genetic mutation features.
共有 174 条符合本次的查询结果, 用时 5.850264 秒